Katogen

Katogen is a biopharma consulting and advisory firm founded in 2016 and headquartered in Boston, MA. Founded by Doug Drysdale, a biopharma executive with 35+ years of operator experience, including 18 years in CEO roles, including at Alvogen - a global generics and specialty pharma company - and Cybin, a clinical-stage psychedelic medicine company, Drysdale has completed 17 acquisitions and raised over USD 4 billion in growth capital across the biopharma sector.

Katogen advises CEOs, founders, and executive teams at growth-stage and mid-sized biopharma and life sciences companies on strategic planning, M&A, integration, capital raises, development planning, novel modalities, drug delivery, supply chain, and reimbursement strategy. Operator-Led Biopharma Consulting The Katogen Difference The biopharma advisory market is crowded. Most firms offer frameworks, benchmarks, and slide decks built from the outside. Katogen offers something different - operator-led strategy grounded in 35+ years of hands-on executive experience across the full biopharma value chain. The difference is measurable.

According to McKinsey, biopharma companies that engage advisors with direct operator experience achieve 2.3x better outcomes on M&A integration versus those using traditional consulting firms. Bain & Company's 2026 Pharmaceuticals M&A Report confirms that biopharma M&A spend nearly doubled in 2025, with nine acquisitions exceeding USD 10 billion - the highest concentration of mega-deals on record. In this environment, the quality of strategic advice has never mattered more. At Katogen, every recommendation is grounded in the decisions, trade-offs, and operational realities that only come from sitting in the CEO chair across multiple companies, cycles, and therapeutic areas.